Patient groups concerned over 'delay' in rare diseases treatment policy implementation

Published On 2018-11-21 03:51 GMT   |   Update On 2018-11-21 03:51 GMT

 New Delhi: Patient's organisations on Tuesday sought immediate implementation of the National Policy for Treatment of Rare Diseases, stating the affected were losing lives due to "delayed response" from the government.


The policy was approved by the Union Health Ministry in May last year, and the Rs 100-crore corpus that was allocated for it has lapsed, claimed an association of patients suffering from Lysosomal Storage Disorders (LSDs).



Several children have lost their lives due to lack of treatment, the Lysosomal Storage Disorders Support Society (LSDSS) said, and claimed that recently a letter was sent to the health ministry, but there was no response.

"Patients are losing lives as the government delays response. We had written a letter to a joint secretary in the health ministry, seeking a response on the initiation of treatment based on applications submitted by patients under the National Policy for Treatment of Rare Diseases. But there was no response," LSDSS president Manjit Singh alleged.


"We have recently also written a letter to the health secretary explaining that the patients are awaiting treatment and requested allocation of funds for the same. Unfortunately, we have not even heard back on the second letter, which is disheartening," he claimed.


Over 160 patients have submitted in the health ministry's Rare Diseases Cell their applications for treatment support, as directed in the policy. However till date, not a single child has been provided the treatment, Singh said.


"Around 20 children have passed away in the intervening period, 10 alone in Tamil Nadu," he alleged.


Highlighting the gaps in the policy, experts said the most difficult task is to bridge the "tedious process of patient application and distribution of funds" for treatment.


The policy talks about setting up of a Central Technical Committee (CTC), individual State Technical Committees (STCs) and Rare Disease Cell for treatment of patients.


While these committees have been set up, experts claim that the process for availing treatment is too complicated and tedious.


"This was ideally supposed to ease processing of patient applications and distribution of funds. Even when some states have identified patients for treatment and formed the STCs, no applications have been processed by CTCs.


"There is no reason that justifies the neglect and laxity on the part of the government. Filing the application is itself a tiring procedure for a patient, who is already struggling with a rare disease," Singh claimed.


Prasanna Shirol, the co-founder and executive director of Organisation for Rare Disease India (ORDI), said some states have shared patient applications with the Centre and requested for funds.


But the central government has taken no action on it. The Centre was supposed to come up with guidelines for setting up a structure to process the applications and providing treatment, said Shirol, whose organisation had also written to the ministry for the implementation of the policy.


"This is like adding insult to injury," he said.


The organisations also expressed disappointment over the "non-utilisation" of Rs 100 crore corpus allocated under the policy.


"The fund was supposed to be used for the benefit of the patients, but none of it has been utilised. This has been the biggest gap as the fund has now lapsed as the last financial year ended," Shirol said.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News